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ORIGINAL ARTICLE
A decoy receptor 3 analogue reduces localised
defects in phagocyte function in
pneumococcal pneumonia
Helen M Marriott,1 Marc Daigneault,1 Alfred A R Thompson,1,2 Sarah R Walmsley,1,2
Sharonjit K Gill,1 Derrick R Witcher,3 Victor J Wroblewski,4 Paul G Hellewell,5
Moira K B Whyte,1,2 David H Dockrell1,2
ABSTRACT
Background Therapeutic strategies to modulate the host
response to bacterial pneumonia are needed to improve
outcomes during community-acquired pneumonia. This
study used mice with impaired Fas signalling to examine
susceptibility to pneumococcal pneumonia and decoy
receptor 3 analogue (DcR3-a) to correct factors
associated with increased susceptibility.
Methods Wild-type mice and those with varying
degrees of impairment of Fas (lpr) or Fas ligand signalling
(gld) were challenged with Streptococcus pneumoniae
and microbiological and immunological outcomes
measured in the presence or absence of DcR3-a.
Results During established pneumonia, neutrophils
became the predominant cell in the airway and gld mice
were less able to clear bacteria from the lungs,
demonstrating localised impairment of pulmonary
neutrophil function in comparison to lpr or wild-type
mice. T-cells from gld mice had enhanced activation and
reduced apoptosis in comparison to wild-type and lpr
mice during established pneumonia. Treatment with
DcR3-a reduced T-cell activation and corrected the
defect in pulmonary bacterial clearance in gld mice.
Conclusions The results suggest that imbalance in
tumour necrosis factor superfamily signalling and excessive
T-cell activation can impair bacterial clearance in the lung
but that DcR3-a treatment can reduce T-cell activation,
restore optimal pulmonary neutrophil function and enhance
bacterial clearance during S pneumoniae infection.
INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is the
commonest cause of community-acquired pneu-
monia (CAP) and causes approximately 2 million
deaths annually.1 Despite advances in antimicrobial
therapy and management of critically ill patients,
therapeutic modulation of the pulmonary inﬂam-
matory response has been relatively neglected in
CAP, even though dysregulation of the inﬂamma-
tory response is a key feature of pathogenesis. To
adopt this strategy we need a better understanding
of factors which regulate susceptibility to CAP, and
how these can be manipulated to ensure an optimal
inﬂammatory response that achieves bacterial
clearance without inﬂammatory lung injury.
The tumour necrosis factor superfamily (TNFSF)
regulates inﬂammatory responses. In this study we
have addressed whether TNFSF member Fas ligand
(FasL, TNFSF6) inﬂuences susceptibility to pneu-
mococcal pneumonia. FasL is a transmembrane
protein that signals through Fas (CD95,
TNFRSF6).2 Multimerised Fas activates apoptosis
in a range of cells, including epithelial cells and
phagocytes, regulating immune homeostasis.3
Alternatively Fas signal transduction contributes to
cell activation and pro-inﬂammatory effects, for
example in the lung FasL contributes to the path-
ogenesis of acute lung injury.4 FasL expression
increases during pneumococcal infection.5 6 During
pneumonia with Gram-positive bacteria there is
less neutrophil recruitment in lpr mice, which have
low levels of functional Fas, or in mice treated with
a decoy receptor 3 analogue (DcR3-a) that
neutralises FasL.6 7 Despite this, bacterial clearance
is enhanced unless a more severe infection is
established, suggesting under certain circumstances
FasL has an adverse effect on disease outcome.6
FasL therefore has key roles in immune homeo-
stasis,8 and host defence.9 It also has the potential
to exacerbate inﬂammatory lung injury, and its role
in bacterial clearance varies depending on the
infection and murine model studied.6 7
We addressed the role of FasL in the pathogenesis
of CAP in murine models of pneumococcal pneu-
monia (see online supplement). We tested the
role of complete FasL deﬁciency using C57BL/6
gld mice, which express FasL lacking functional
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activity.10 The results were compared with wild-type C57BL/6
mice and C57BL/6 mice carrying the lpr mutation, which results
in reduced expression of Fas,11 but less than complete inhibition
of Fas signalling, since the mutation is leaky.12 13 We also
compared results in these mice with the effect of FasL neutral-
isation with DcR3-a. DcR3-a is an analogue of DcR3
(TNFRSF6B) which neutralises FasL but also inhibits two other
TNFSF members: TNFSF14 (lymphotoxin-related inducible
ligand which competes for glycoprotein D binding to herpes
virus entry mediator on Tcells; LIGHT) and TNFSF15 (TNF-like
protein 1A; TL1A).14e16 This allowed us to compare the effects
of selective versus non-selective FasL neutralisation that also
included other TNFSF members to determine their potential role
in the pathogenesis of CAP and to examine the therapeutic
potential of manipulation of TNFSF signalling during CAP.
Our murine models suggest inhibition of FasL signalling
enhances T-cell activation and impedes bacterial clearance but
that these alterations can be corrected by administration of
a TNFSF decoy receptor 3 analogue (DcR3-a).
MATERIAL AND METHODS
Animals
Adult female mice, homozygous for the FasLgld mutation (B6Smn.
C3-Faslgld/J) and Faslpr(B6.MRL-Faslpr/J), on a C57BL/6 back-
ground (Jackson Laboratories, Bar Harbour, Maine, USA) were
used.10 11 C57BL/6 mice were used as wild-type controls. All
animal experiments were conducted in accordance with the Home
Ofﬁce Animals (Scientiﬁc Procedures) Act 1986 and approved by
the University of Shefﬁeld Ethical Review Committee.
Pneumococcal infection model
Pulmonary infection of mice was by direct tracheal instillation
as described previously.17 Neutrophil depletion was with 100 mg/
mouse Gr-1 antibody or isotype control. Decoy receptor treatment
was with 400 mg/mouse DcR3-a or bovine serum albumin (BSA).
For detailed methods see online supplement. Viable bacteria in
lung and blood were measured and cell differential was assessed by
morphology on cytospins.17 Apoptosis detection was by nuclear
morphology or Annexin VdTopPro 3 staining and ﬂow cytom-
etry, with neutrophils being identiﬁed by Ly6G staining and
forward/side scatter characteristics as described.17
In vitro neutrophil function
Peripheral blood neutrophils were isolated by negative magnetic
selection with cell purity routinely greater than 80%.18 Rates of
apoptosis were assessed by morphology on cytospins after 9 h of
culture. For apoptosis after bacterial infection neutrophils
were infected with serotype 2 S pneumoniae (multiplicity of
infection (MOI) ¼10) and apoptosis assessed at 9 h post infection
by nuclear morphology. Respiratory burst was assessed by ﬂow
cytometry analysis of dichlorodihydroﬂuorescein ﬂuorescence
following 30 min of stimulation by heat-killed serotype 2 S
pneumoniae (MOI¼10). Phagocytosis was assessed by calculating
the phagocytic index on cytospins of neutrophils incubated with
opsonized zymosan (20 mg/ml) for 30 min; internalised particles
were counted as those within a phagocytic vacuole.
Isolation and staining of splenocytes
Mice received 13107 colony-forming units (CFUs) of serotype 4 S
pneumoniae and after 24 h were killed by overdose of anaesthetic
and exsanguination. Spleens were collected, splenocytes isolated
and activation of CD3+ Tcells measured by ﬂow cytometry (LSR
II, BD Biosciences, Oxford, UK) as percentage of CD25+ cells.
Apoptosis was measured as the percentage of cells with hypo-
diploid DNA after propidium iodide staining.19 Analysis was with
FlowJo software V.9.3.2 (Tree Star, Inc, Ashland, Oregon, USA).
Statistics
Statistical analysis was by analysis of variance (parametric data),
t test (parametric data), KruskaleWallis (non-parametric data),
ManneWhitney (non-parametric data) or log-rank test for
survival, using Prism 5.0 software (GraphPad Inc, La Jolla,
California, USA). Differenceswere considered signiﬁcant if p<0.05.
RESULTS
Reduced bacterial clearance in gld mice with established
pneumonia
We examined the outcome of infection using three models of
infection with high inocula of S pneumoniae. There was an
increase in CFUs in lung and blood, 24 h after infection, in the
gld mice compared with C57BL/6 and lpr mice (which had
similar CFUs), after both serotype 1 (ﬁgure 1A,B) and serotype 2
infection (ﬁgure 1D,E). Serotype 4 infections resulted in higher
bacterial CFUs in lung or blood of wild-type and lpr mice but the
increase in CFUs for gld mice was not signiﬁcant (ﬁgure 1G,H).
FasL contributes to CXC chemokine expression in the lung and
to neutrophil recruitment into the airspaces in response to
a variety of stimuli including pneumococci.6 20 We documented
impaired neutrophil recruitment into the lung in the absence of
Fas signalling in both gld and lpr mice 24 h after challenge with
serotype 1 S pneumoniae (ﬁgure 1C). After infection with the more
virulent serotypes 2 or 4 S pneumoniae, neutrophil numbers were
similar between strains at 24 h (ﬁgure 1F,I). Fas can trigger
neutrophil apoptosis.3 Since absolute levels of neutrophil apoptosis
in vivo in the lung are inﬂuenced by the rate of apoptosis induc-
tion and the rate of clearance of apoptotic cells, while the
percentage of apoptotic cells is confounded by rates of neutrophil
recruitment, we measured rates of constitutive apoptosis in vitro.
We conﬁrmed reduced rates of constitutive apoptosis in peripheral
blood neutrophils from lpr and gldmice, but found no reduction in
neutrophil apoptosis in the presence of pneumococci in vitro and
conﬁrmed this ﬁnding in vivo (ﬁgure 2AeC).
Dysfunctional pulmonary neutrophil responses in gld mice
We next addressed the functional capacity of phagocytes. As gld
mice had no reduction in alveolar macrophage-dependent
bacterial clearance (online supplementary ﬁgure 3) we addressed
the functional capacity of neutrophils. Since the number of
bacteria inside neutrophils reﬂects rates of ingestion and killing
we measured rates of zymosan uptake as a marker of phagocytic
capacity. Peripheral blood neutrophils from gld and lpr mice had
no intrinsic defect in phagocytosis or in generation of reactive
oxygen species when challenged with heat-killed S pneumoniae
ex vivo (ﬁgure 3A,B). To address the contribution of neutrophils
to bacterial clearance in vivo we reduced neutrophil numbers
with anti-Gr1 antibody (ﬁgure 4A, online supplementary
ﬁgure 2) and examined clearance of serotype 2 S pneumoniae at
14 h after infection, to ensure the phagocytes were recently
recruited.21 Although anti-Gr-1 also depletes monocytes these
made up only about 1% of bronchial alveolar lavage cells at this
time point. The anti-Gr-1 treatment signiﬁcantly increased
CFUs in the lung and blood of C57BL/6 and lpr mice but not gld
mice (ﬁgure 4B,C). Since the defect in bacterial CFUs was more
marked for gld mice in blood than in lung we also investigated
whether these mice were less able to clear bacteria from blood. A
tail vein injection of 103 CFUs showed equivalent bacterial
clearance in C57BL6 and gld mice (data not shown).
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Results at 48 h after high-dose serotype 2 infection also revealed
increased CFUs in gld mice (ﬁgure 5A,B) though to a lesser extent
than at 24 h (ﬁgure 1D,E), with reduced neutrophil counts (ﬁgure
5C). In keeping with these ﬁndings gld mice had increased
mortality in comparison to wild-type mice in the period from 72
to 120 h (ﬁgure 5D). At 72 h there was 40% survival in the gld
mice versus 70% in the wild-type mice and the median survival in
gld mice was 72 h versus undeﬁned in the wild-type mice,
although overall survival did not differ (p¼0.5033).
Alterations in the levels of T-cell activation and apoptosis in gld
mice
Since accumulation of activated T cells is an early feature of
pneumococcal pneumonia and T-cell responses are required for
optimal clearance of bacteria,22 23 we next examined levels of T-
cell activation in each mouse strain by studying levels of CD25+
CD3+ Tcells in cells isolated 24 h after infection. We used high-
dose type 4 S pneumoniae to ensure all mice had equivalent levels
of bacteraemia. As shown there were greater levels of CD3+ T-
cell activation in gld mice (ﬁgure 6A) and these mice had lower
levels of apoptotic T cells (ﬁgure 6B).
DcR3-a corrects the impairment in bacterial clearance
associated with FasL deficiency
The decoy receptor DcR3 not only neutralises FasL but also
additional TNFSF members LIGHTand TL1A and can modify T-
cell activation.24 25 We reasoned if the impaired clearance of
bacteria was solely due to FasL deﬁciency then DcR3 would
replicate the gld phenotype in C57BL/6 and lpr mice but have no
effect upon gld mice. To test this we utilised a modiﬁed analogue
of DcR3, DcR3-a (FLINT), which is more resistant to proteolytic
cleavage in vivo than the parental structure.6 26 DcR3-a inhibits
Figure 1 Reduced bacterial clearance
in gld mice with established pneumonia.
(A) Colony-forming units (CFUs) of
bacteria in lung homogenates from
wild-type control mice (WT) and mice
deficient in Fas ligand (gld) or Fas (lpr)
24 h after intratracheal instillation of
107 CFUs of serotype 1 pneumococci;
(B) CFUs of bacteria in blood in the
same experiments as (A); (C)
percentage of neutrophils (PMN) in
bronchial alveolar lavage (BAL) from the
same experiments as (A); (D) CFUs of
bacteria in lung homogenates from mice
24 h after intratracheal instillation of
107 CFUs of serotype 2 pneumococci;
(E) CFUs of bacteria in blood in the
same experiments as (D); (F)
percentage of neutrophils in BAL from
the same experiments as (D); (G) CFUs
of bacteria in lung homogenates from
mice 24 h after intratracheal instillation
of 107 CFUs of serotype 4
pneumococci; (H) CFUs of bacteria in
blood in the same experiments as (G);
(I) percentage of neutrophils in BAL
from the same experiments as (G). (A,
B, D, E, G, H) Line at median,
KruskaleWallis test with Dunn’s
multiple comparison test; (C, F, I): mean
+SEM, analysis of variance with
Bonferroni’s multiple comparison test,
*p<0.05, **p<0.01, ***p<0.001,
n¼12e15.
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FasL, LIGHT and TL1A in vivo and has modiﬁed bacterial
clearance in other models of pneumococcal pneumonia.6 26
Surprisingly we did not ﬁnd any difference in bacterial CFUs in
the lungs or blood of C57BL/6 and lpr mice in the presence or
absence of DcR3-a (ﬁgure 7A,B) following infection with
a moderate dose of serotype 4 pneumococci, which resulted in
only low levels of neutrophil recruitment (ﬁgure 7C). In
contrast, the defect in bacterial clearance was corrected in the gld
mice. DcR3-a also reversed the increased levels of T-cell activa-
tion observed in gld mice (ﬁgure 8).
DISCUSSION
We demonstrate that gld mice are impaired in their ability to
clear bacteria from the lung in a model of pneumococcal pneu-
monia. We show enhanced T-cell activation is associated with
localised pulmonary defects in neutrophil function in gld mice.
DcR3-a, which neutralises FasL, had no effect on bacterial
clearance in wild-type or lpr mice but corrected the defects in
bacterial clearance in gld mice and reduced levels of T-cell acti-
vation, suggesting unopposed T-cell activation by other TNF
superfamily members, inhibitable by DcR3-a, inﬂuenced bacte-
rial clearance in gld mice. These results suggest that altered
balance of TNFSF signalling, involving FasL and other DcR3
ligands, adversely inﬂuences the outcome of pneumonia during
a deﬁned period when initial neutrophil and T-cell recruitment
are required to control infection and at a deﬁned threshold of
infection when resident host responses fail.22 23
Figure 2 Mice lacking Fas ligand have reduced constitutive neutrophil
apoptosis but no defect in apoptosis in the presence of bacteria.
Peripheral blood neutrophils from wild-type control mice (WT) and mice
deficient in Fas ligand (gld) or Fas (lpr) were isolated by negative
magnetic selection. (A) Rates of apoptosis were assessed by
morphology on cytospins prepared after 9 h of culture, n¼4. (B)
Neutrophils were infected with pneumococci (MOI¼10) and apoptosis
assessed as in A, n¼3. (C) Apoptosis of neutrophils in bronchial alveolar
lavage from WT control mice or mice deficient in Fas ligand (gld) 24 h
after intratracheal instillation of 107 colony-forming units (CFUs) of
serotype 2 pneumococci, n¼14 WT and 10 gld. Mean+SEM, analysis of
variance with Bonferroni’s multiple comparison test, *p<0.05,
***p<0.001.
Figure 3 Mice lacking Fas ligand have preserved neutrophil function ex
vitro. Peripheral blood neutrophils from wild-type control mice (WT) and
mice deficient in Fas ligand (gld) or Fas (lpr) were isolated by negative
magnetic selection. (A) Phagocytosis was assessed by calculating
phagocytic index on cytospins of peripheral blood neutrophils incubated
with opsonized zymosan (20 mg/ml) for 30 min, n¼5. (B) Respiratory
burst was assessed by flow cytometry analysis of dichlorodihydro-
fluorescein (DCF) fluorescence following 30 min of stimulation by heat-
killed serotype 2 pneumococci (MOI¼10). Geometric mean fluorescence
(GMF), n¼3. Mean+SEM, analysis of variance with Bonferroni’s
multiple comparison test, p ¼ not significant.
Figure 4 Absence of Fas ligand impairs neutrophil function in vivo.
Wild-type control mice (WT) and mice deficient in Fas ligand (gld) or Fas
(lpr) were treated with anti-Gr1 antibody to deplete neutrophils (PMN)
(anti-Gr1) or isotype control (iso) 24 h prior to intratracheal instillation of
107 colony-forming units (CFUs) of serotype 2 pneumococci. Fourteen
hours post infection (A) the percentage of neutrophils in bronchial
alveolar lavage was assessed, mean+SEM, analysis of variance with
Bonferroni’s multiple comparison test; (B) CFUs of bacteria in lung
homogenates; (C) CFUs of bacteria in blood, line at median,
KruskaleWallis test with Dunn’s multiple comparison test, *p<0.05,
**p<0.01, ***p<0.001, n¼9e10.
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The effects of complete and selective inhibition of Fas
signalling on pneumococcal pneumonia, to our knowledge, have
not previously been addressed. We did not predict a difference
between gld and lpr mice. Both mutations are loss of function
mutations that impair Fas signalling leading to autoimmune
manifestations13 and we conﬁrmed the development of
lymphadenopathy and splenomegaly as gld and lpr mice aged.
The extent of inhibition of Fas signalling in lpr mice is less
complete than that observed in gld mice.12 13 The lpr mutation
results from the insertion of an early transposable element into
intron 2 and is leaky with residual low-level expression of Fas.12
In contrast, the gld mutation introduces a point mutation into
the C-terminus of FasL and blocks binding of FasL to Fas.10
These result in subtle differences in the inﬂammatory response
between strains.20 Of immediate relevance gld mice have a more
profound reduction in peripheral blood CD4+, CD4+ CD25+
FoxP3+, and most markedly CD8+ T cells.27 We found reduced
neutrophil-dependent bacterial clearance and enhanced T-cell
activation occurred only in gld mice, suggesting residual Fas
signalling activity in lpr mice may have been sufﬁcient to ensure
optimal host responses and to prevent the more marked
perturbations in T-cell subsets previously described in gld mice.27
We show an early requirement for FasL at the stage of pneu-
monia when neutrophils start to be recruited to the lung. Under
these circumstances absolute and selective deﬁciency of FasL
was associated with enhanced activation of T cells and reduced
pulmonary neutrophil function. Residual Fas signalling, as
evidenced by lpr mice, is sufﬁcient for host defence but complete
deﬁciency exposes the host to harmful effects of other TNFSF
members. The concept that the unopposed actions of other
TNFSF members may mediate speciﬁc phenotypes during
impairment of Fas signalling is not without precedent since
neutralisation of TNF-a attenuates the generalised lymphade-
nopathy of gld mice.28
Figure 5 The difference in bacterial
outcome between wild-type (WT) mice
and mice deficient in Fas ligand (gld) is
reduced at later time points. (A) Colony-
forming units (CFUs) of bacteria in lung
homogenates from WT control mice
(n¼14) and gld mice (n¼12) 48 h after
intratracheal instillation of 13107 CFUs
of serotype 2 pneumococci. (B) CFUs of
bacteria in blood in the same
experiments as (A), line at median,
ManneWhitney. (C) The percentage of
neutrophils (PMN) in bronchial alveolar
lavage in the same experiments as (A),
mean+SEM, t test, **p<0.01. (D) WT
(n¼11) and gld mice (n¼12) were
instilled with 107 CFUs of type 2
pneumococci and followed for 10 days.
Median survival: WT, undefined; gld,
72 h; log-rank test p¼0.5033.
Figure 6 Alterations in levels of T-cell activation and apoptosis in mice
deficient in Fas ligand (gld). Splenocytes were isolated from spleens of
wild-type control mice (WT) and gld mice or mice deficient in Fas (lpr)
24 h after intratracheal instillation of 107 colony-forming units of
serotype 4 pneumococci and CD3+ T cells identified by flow cytometry.
(A) Activation was measured by the levels of CD25 cells (n¼3). (B)
Apoptosis was measured by analysing the percentage of cells with
hypodiploid DNA after propidium iodide staining (% Sub G0/1, n¼5),
mean+SEM, analysis of variance with Bonferroni’s multiple comparison
test, *p<0.05.
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Fas signalling inﬂuenced neutrophil recruitment and rates of
constitutive apoptosis, as previously documented.6 It did not
alter rates of neutrophil apoptosis after bacterial infection.
Overall this resulted in variable differences in neutrophil
numbers in the lung. Differences in neutrophil numbers alone do
not explain the selective impairment in host defence of the gld
mice and there was no intrinsic deﬁcit in neutrophil function in
either lpr or gld mice. The functional neutrophil impairment in
bacterial clearance was conﬁned to the lung since clearance from
the blood was normal following intravenous challenge. We
conclude that there was a localised defect in the phagocytosis or
killing of bacteria by pulmonary neutrophils in gld mice. Fas
signalling can modify toll-like receptor responses27 but the
absence of macrophage or intrinsic neutrophil defects argues
against this being an important factor. The unique defects we
identiﬁed in gld mice were characterised by selective alteration in
pulmonary neutrophil function and were associated with
increased T-cell activation.
The role of T cells in the innate response to pneumococcal
pneumonia has been controversial. T helper (Th) 17 T cells
contribute to phagocytic function during upper airway coloni-
sation while CD4+ Tcells are necessary for optimal clearance of
bacteria from the lung in the initial stages of pneumonia.22 23 In
contrast, selective CD4+ T-cell depletion or non-selective T-cell
inhibition reduces invasive disease29 but CD8+ T-cell depletion
worsens pneumonia outcome.30 Our results suggest that FasL-
dependent regulation of activated Tcells could be a key factor in
ensuring optimal pneumococcal clearance by pulmonary
neutrophils early in the course of pneumonia and if this fails
there is a more rapid progression to mortality. Since gld mice
have relatively lower numbers of CD8+ Tcells,27 and these cells
can prominently express FasL, our results are consistent with an
early role for these cells in pneumonia. Important roles for other
T-cell populations such as CD4+ T-cells are equally possible in
keeping with observations that T-cell depletion in fulminant
disease is beneﬁcial, since the concept of improving outcomes by
reducing host responses in more fulminant disease are well
established.21 However, alterations in T-cell activation may be
crucial. The gld phenotype is associated with a large population
of preactivated T cells, which leads to hypersecretion of Th1
cytokines and localised perturbation of cytokine networks could
alter neutrophil function.31 Excess T-cell activation harms host
defence; Th1-derived cytokines impair innate function when
present at inappropriately high or sustained levels; interferon g
can inhibit Fcg-mediated phagocytosis and intracellular killing
of bacteria.32 33 Therefore excessive immune activation may
Figure 7 Decoy receptor 3 analogue (DcR3a) corrects the impairment
in bacterial clearance associated with Fas ligand deficiency. Wild-type
control mice (WT) and mice deficient in Fas ligand (gld) or Fas (lpr) were
treated with DcR3a or BSA control (BSA) immediately prior to
intratracheal instillation of 53105 colony-forming units (CFUs) of
serotype 4 pneumococci and 12 h post infection. Twenty-four hours post
infection, (A) CFUs of bacteria in lung homogenates. (B) CFUs of bacteria
in blood in the same experiments as (A), line at median, KruskaleWallis
test with Dunn’s multiple comparison test. (C) The percentage of
neutrophils (PMN) in bronchial alveolar lavage in the same experiments
as (A) and (B) were estimated, mean+SEM, analysis of variance with
Bonferroni’s multiple comparison test, *p<0.05, n¼8e16.
Figure 8 T-cell activation is reduced in mice deficient in Fas ligand
(gld) after decoy receptor 3 analogue (DcR3a) treatment. Wild-type
control mice (WT) and gld mice were treated with DcR3a or BSA control
(BSA) immediately prior to intratracheal instillation of 13107 colony-
forming units (CFUs) of serotype 4 pneumococci. Splenocytes were
isolated from spleens 24 h after infection, and the percentage of CD25+
CD3+ T cells recorded by flow cytometry, mean+SEM, analysis of
variance with Bonferroni’s multiple comparison test, *p<0.05, n¼3e6.
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have a paradoxical effect on innate responses to S pneumoniae in
the lung and be as harmful as deﬁciency. Reducing T-cell acti-
vation during selective FasL deﬁciency or in fulminant disease
can improve pneumonia outcome.29
Termination of immune responses requires FasL-induced T-cell
apoptosis during sustained responses to micro-organisms.8
DcR3-a reduced T-cell activation and the defect in neutrophil-
dependent bacterial clearance in gld mice, suggesting unopposed
LIGHT/TL1A mediate the inappropriate T-cell activation in gld
mice. Consistent with this possibility T-cell derived LIGHT/TL1A
drive Th1 and Th17 cytokine expression at mucosal surfaces34 35
and favour dysregulated inﬂammatory responses.36 37 Although
DcR3-a could alter neutrophil or macrophage responses directly
the absence of evidence of macrophage or intrinsic neutrophil
defects make this unlikely.
The beneﬁts of FasL in our model are consistent with
requirements for FasL to regulate T-cell activation during the
early evolution of pulmonary neutrophil responses. The results
of Matute-Bello et al suggest incomplete (lpr mice) or non-
selective inhibition (DcR3-a) of Fas at a later stage of pneumo-
coccal pneumonia improve outcomes.6 Reduction of neutrophil
numbers or function, when these exceed the optimal amount
required for bacterial clearance, can improve outcome21 38 and
we believe the effects Matute-Bello et al observed are consistent
with this requirement to decrease neutrophil responses. We
found that lpr or DcR3-a-treated wild-type mice had no worse
outcome than wild-type mice, while only the complete but
selective inhibition of FasL in gld mice worsened outcome in all
but the most advanced stages of pneumonia. It therefore seems
that FasL signalling and that of related TNFSF ligands must be
ﬁnely tuned to ensure optimal host responses during pneumonia
(online supplementary ﬁgure 4).
Examination of clinical cohorts will be required to tease out
these paradigms and conﬁrm the therapeutic potential in CAP.
Although lpr/gld mice are useful models of immune homeostasis
and clinical diseases, as the murine phenotype varies considerably
with genetic background, translation in clinical studies is essential.8
The potential translational implications are that manipulation of
TNFSF ligands, an emerging therapeutic approach in oncology and
other settings,39 could improve the outcome of CAP. Increased FasL
expression has been documented in patients with pneumococcal
infection.5 6 Documentation of relative decreases in FasL expres-
sion, altered ratios of DcR3 ligand expression leading to increased
LIGHT/TL1A relative to FasL or enhanced T-cell activation in
patients with worse clinical outcomes could trigger TNFSF ligand
neutralisation using DcR-3 neutralisation or similar approaches
early in pneumonia. This approach might also be beneﬁcial when
there is excessive neutrophilic inﬂammation later in disease. Our
ﬁndings suggest that T-cell activation must be tightly controlled
and conﬁrm an important role for FasL expression in regulating
host responses during pneumococcal pneumonia. These results also
suggest modulation of DcR3 ligands could represent an unex-
ploited therapeutic strategy that improves outcomes during CAP.
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